17 results
8-K
RVNC
Revance Therapeutics Inc
9 May 24
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
4:08pm
an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
ITEM 8.01 OTHER
8-K
RVNC
Revance Therapeutics Inc
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely
8-K
EX-99.1
u8386on
27 Nov 20
Other Events
1:50pm
424B3
kfj1u49qwknea8
24 Jun 20
Prospectus supplement
5:18pm
S-4/A
a512qi9
23 Jun 20
Registration of securities issued in business combination transactions (amended)
6:09am
S-4
rao69c8y8p1ydvobf
9 Jun 20
Registration of securities issued in business combination transactions
9:48pm
S-1
EX-10.12
8sw3yia3blyfemerufj
31 Dec 13
IPO registration
12:00am
DRS
EX-10.12
xr8ya9jq1et ss9
19 Apr 13
Draft registration statement
12:00am
- Prev
- 1
- Next